Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Non Operating Income (2016 - 2025)

CytomX Therapeutics' Non Operating Income history spans 12 years, with the latest figure at -$5000.0 for Q4 2025.

  • For Q4 2025, Non Operating Income rose 73.68% year-over-year to -$5000.0; the TTM value through Dec 2025 reached $28000.0, up 171.79%, while the annual FY2025 figure was $28000.0, 173.68% up from the prior year.
  • Non Operating Income reached -$5000.0 in Q4 2025 per CTMX's latest filing, down from $5000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $296000.0 in Q2 2022 to a low of -$82000.0 in Q2 2021.
  • Average Non Operating Income over 5 years is $10800.0, with a median of $3000.0 recorded in 2021.
  • Peak YoY movement for Non Operating Income: crashed 1740.0% in 2021, then surged 950.0% in 2025.
  • A 5-year view of Non Operating Income shows it stood at $7000.0 in 2021, then crashed by 85.71% to $1000.0 in 2022, then skyrocketed by 800.0% to $9000.0 in 2023, then tumbled by 311.11% to -$19000.0 in 2024, then skyrocketed by 73.68% to -$5000.0 in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Non Operating Income are -$5000.0 (Q4 2025), $5000.0 (Q3 2025), and $17000.0 (Q2 2025).